Vita 34 AG extends the acceptance period under PBKM exchange offer
DGAP-News: Vita 34 AG / Key word(s): Miscellaneous
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS
Vita 34 AG extends the acceptance period under PBKM exchange offer
– Vita 34 extended the acceptance period under its exchange offer for all shares in PBKM to 2 November 2021, 24:00 hours (CET).
Leipzig/Warsaw, 11 October 2021 – On 20 September 2021, Vita 34 AG (“Vita 34“, ISIN: DE000A0BL849; WKN: A0BL84), Leipzig, announced the start of the acceptance period for the voluntary exchange offer (“Exchange Offer“) for all outstanding shares in Polski Bank Komórek Macierzystych S.A., Warsaw (“PBKM“, ISIN: PLPBKM000012; WKN: A2AJKP). Vita 34 is offering 1.3 new Vita 34 shares in exchange for each PBKM share.
The acceptance period under the Exchange Offer started on 20 September 2021 and was originally set to expire on 18 October 2021. Following the approval of a supplement to the securities prospectus by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and the notification of the supplement to the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), Vita 34 has extended the acceptance period to 2 November 2021, 24:00 hours (CET).
Subject to the fulfilment or waiver of the offer conditions, which, inter alia, include a minimum acceptance threshold of 95%, the Exchange Offer is now expected to be settled on 15 November 2021.
This announcement does neither constitute an offer to exchange or purchase nor the solicitation of an offer to exchange or purchase any securities. Moreover, this announcement does neither constitute an offer to buy nor the solicitation of an offer to buy any securities in PBKM or Vita 34. The final terms and further provisions regarding the Exchange Offer are published in the securities prospectus (including its supplements) which publication has been permitted by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht). Investors and holders of PBKM shares are strongly recommended to read the securities prospectus (including its supplements) and all other documents in connection with the Exchange Offer as soon as they are published, as they will contain important information.
Subject to the exceptions described in the securities prospectus and any exceptions granted by the relevant regulatory authorities, an Exchange Offer is not being made, directly or indirectly, in or into those jurisdictions where to do so would constitute a violation pursuant to the laws of such jurisdiction.
In particular, the Exchange Offer is not being made and the Vita 34 shares that are intended to be transferred to PBKM shareholders as consideration (the “Vita 34 Offer Shares“) may not be offered, sold or delivered, directly or indirectly, in or into the United States of America (including its territories and possessions, any State of the United States and the District of Columbia) (“United States“), Australia, Canada, Japan or South Africa. The Vita 34 Offer Shares have not been, and will not be registered, under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“), or under the securities laws of any state, district or other jurisdictions of the United States.
About Vita 34
Vita 34 was founded in 1997 in Leipzig and is today one of the leading cell banks in Europe. As Europe’s first private cord blood bank and a pioneer in cell banking, the company has since offered collection logistics, processing and storage of stem cells from umbilical cord blood and tissue as a full-service provider for cryopreservation. Based on the expansion of the business model in 2019, Vita 34 also intends to offer the storage of immune cells from peripheral blood and stem cells from autologous fat in the future. Endogenous cells are a valuable starting material for medical cell therapy and are kept alive at temperatures around minus 200 degrees Celsius so that they can be used as part of a treatment if required. More than 247,000 customers from more than 20 countries have already provided for their family’s health with a cell depot at Vita 34.
For more information: https://ir.vita34.de/en/
Polski Bank Komórek Macierzystych leads the international FamiCord Group, which manages stem cell banks located in Europe. FamiCord Group stores 610.000 samples belonging to over 450,000 families. FamiCord’s core business is the procurement, processing and long-term storage of stem cells from umbilical-cord blood and other post-foetal tissues on behalf of parents (family banking). The purpose of this banking is to provide security for the family in the event of a serious illness which requires a stem cell transplant in the donor or his/her immediate family members.
The FamiCord Group is now present in over 35 European countries. It directly offers services to clients in Poland, Turkey, Spain, Portugal, Hungary, Romania, Switzerland, Italy, Luxembourg, Germany, Latvia, Lithuania and Estonia, and more recently in the Czech Republic, Slovakia, Great Britain, Middle East (Dubai, Abu Dhabi, Lebanon) and Hong Kong. It is one of the leading companies in almost all of these countries. In addition, it provides services to partners who acquire clients in Sweden, Denmark, Serbia and the Balkan countries, Italy and Ukraine. The Group’s services are provided through a network of its own banks and through cooperating banks located in Switzerland, Sweden, Ukraine, the USA and other countries.
In addition, the Group invests in the development of advanced therapy medicinal product (ATMP) manufacturing services, considered to be one of the most important developments in medicine. The PBKM Group is also involved in close to 10 clinical trials, in which stem cell fraction drugs have already been administered to patients about 700 times.
Since May 2016, PBKM has been listed on the main market of the Warsaw Stock Exchange.
Investor Relations contact Vita 34: Ingo Middelmenne, Middelmenne & Cie., Tel +49 (0)341 48792-40, Email: firstname.lastname@example.org
Media contact PBKM: Michał Wierzchowski, cc group, Tel: +48 531 613 067, Email email@example.com
|Company:||Vita 34 AG|
|Deutscher Platz 5a|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1239652|
|End of News||DGAP News Service|